Literature DB >> 35718420

Cardiac Amyloidosis.

Morie A Gertz1.   

Abstract

Amyloid deposits are defined by their tinctorial properties. Under the light microscope amyloid deposits are eosinophilic and amorphous when stained with hematoxylin and eosin. With Congo red staining the deposits are positive and under polarized light will exhibit green birefringence. Sixty years later electron microscopy demonstrated that all deposits were fibrillar. All amyloid deposits are protein derived. The clinical characteristics will be driven by the nature of the protein subunit. In cardiology, the 2 most common subunits accounting for well more than 90% of cardiac amyloidosis are either immunoglobulin light chain, amyloid light-chain (AL) amyloidosis, or transthyretin; transthyretin (TTR) amyloidosis. Although 70% of patients with systemic amyloidosis have cardiac involvement the diagnosis is made by cardiologists only 20% of the time, suggesting significant gaps in knowledge in how to establish a workflow to arrive at a diagnosis in everyday practice. Published by Elsevier Inc.

Entities:  

Keywords:  Amyloid echocardiography; Amyloidosis; Cardiac transplantation; Chemotherapy; Light chains; Stem cell transplantation; Transthyretin

Mesh:

Substances:

Year:  2022        PMID: 35718420      PMCID: PMC9219033          DOI: 10.1016/j.hfc.2022.02.005

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   2.828


  62 in total

Review 1.  Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.

Authors:  Morie A Gertz; Morton Scheinberg; Márcia Waddington-Cruz; Stephen B Heitner; Chafic Karam; Brian Drachman; Sami Khella; Carol Whelan; Laura Obici
Journal:  Expert Rev Clin Pharmacol       Date:  2019-07-03       Impact factor: 5.045

2.  Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?

Authors:  Arnault Galat; Aziz Guellich; Diane Bodez; Michel Slama; Marina Dijos; David Messika Zeitoun; Olivier Milleron; David Attias; Jean-Luc Dubois-Randé; Dania Mohty; Etienne Audureau; Emmanuel Teiger; Jean Rosso; Jean-Luc Monin; Thibaud Damy
Journal:  Eur Heart J       Date:  2016-02-22       Impact factor: 29.983

3.  Beyond NEOD001 for systemic light-chain amyloidosis.

Authors:  Cindy Varga; Suzanne Lentzsch; Raymond L Comenzo
Journal:  Blood       Date:  2018-09-21       Impact factor: 22.113

4.  Grading cardiac response in AL amyloidosis: implications for relapse and survival.

Authors:  Erik Eckhert; Ronald Witteles; Gregory Kaufman; Richard Lafayette; Sally Arai; Stanley Schrier; Michelle O'Shaughnessy; Michaela Liedtke
Journal:  Br J Haematol       Date:  2018-12-19       Impact factor: 6.998

5.  Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.

Authors:  Daniel P Judge; Stephen B Heitner; Rodney H Falk; Mathew S Maurer; Sanjiv J Shah; Ronald M Witteles; Martha Grogan; Van N Selby; Daniel Jacoby; Mazen Hanna; Jose Nativi-Nicolau; Jignesh Patel; Satish Rao; Uma Sinha; Cameron W Turtle; Jonathan C Fox
Journal:  J Am Coll Cardiol       Date:  2019-03-15       Impact factor: 24.094

6.  First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Authors:  Morie A Gertz; Heather Landau; Raymond L Comenzo; David Seldin; Brendan Weiss; Jeffrey Zonder; Giampaolo Merlini; Stefan Schönland; Jackie Walling; Gene G Kinney; Martin Koller; Dale B Schenk; Spencer D Guthrie; Michaela Liedtke
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

7.  Amyloid cardiomyopathy: a hidden heart failure cause that is often misdiagnosed.

Authors:  Yale Tung-Chen; Miguel-Ángel Arnau
Journal:  Acta Clin Belg       Date:  2018-04-17       Impact factor: 1.264

8.  Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy.

Authors:  Antonio Vitarelli; Silvia Lai; Maria Teresa Petrucci; Carlo Gaudio; Lidia Capotosto; Enrico Mangieri; Serafino Ricci; Giuseppe Germanò; Simone De Sio; Giovanni Truscelli; Federico Vozella; Mario Sergio Pergolini; Marcello Giordano
Journal:  Int J Cardiol       Date:  2018-07-23       Impact factor: 4.164

9.  Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis.

Authors:  Kevin M Alexander; John Orav; Avinainder Singh; Sophia A Jacob; Adil Menon; Robert F Padera; Marie F Kijewski; Ronglih Liao; Marcelo F Di Carli; Jacob P Laubach; Rodney H Falk; Sharmila Dorbala
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

Review 10.  Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.

Authors:  Joel N Buxbaum; Frederick L Ruberg
Journal:  Genet Med       Date:  2017-01-19       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.